Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters

References

• Agarwal, S., Chinn, L., and Zhang, L., 2013. An overview of transporter information in package inserts of recently approved new molecular entities. Pharmaceutical research, 30 (3), 899–910.
   PubMed Web of Science ®Google Scholar
• Aitken, A.E., Richardson, T.A., and Morgan, E.T., 2006. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annual review of pharmacology and toxicology, 46 (1), 123–149.
   PubMed Web of Science ®Google Scholar
• Alim, K., et al., 2020. Interactions of Janus kinase inhibitors with drug transporters and consequences for pharmacokinetics and toxicity. Expert opinion on drug metabolism & toxicology, Epub ahead of print. doi:10.1080/17425255.2021.1862084
   Web of Science ®Google Scholar
• Belzer, M., et al., 2013. Substrate-dependent ligand inhibition of the human organic cation transporter OCT2. Journal of pharmacology and experimental therapeutics, 346 (2), 300–310.
   PubMed Web of Science ®Google Scholar
• Bentz, J., et al., 2013. Variability in P-glycoprotein inhibitory potency (IC50) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug metabolism and disposition, 41 (7), 1347–1366.
   PubMed Web of Science ®Google Scholar
• Berg, T., et al., 2018. Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals. Respiratory research, 19 (1), 68.
   PubMedGoogle Scholar
• Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry, 72 (1-2), 248–254.
   PubMed Web of Science ®Google Scholar
• Burckhardt, G., 2012. Drug transport by organic anion transporters (OATs). Pharmacology & therapeutics, 136 (1), 106–130.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research, 2011. Data FDA ruxolitinib transporters [online]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202192Orig1s000ClinPharmR.pdf [Accessed 27 April 2020].
   Google Scholar
• Chedik, L., et al., 2017. Inhibition of human drug transporter activities by the pyrethroid pesticides allethrin and tetramethrin. PLoS One, 12 (1), e0169480.
   PubMed Web of Science ®Google Scholar
• Ebert, C., et al., 2016. Expression and function of ABC-transporter protein ABCB1 correlates with inhibitory capacity of ruxolitinib in vitro and in vivo. Haematologica, 101 (3), e81–e85.
   PubMed Web of Science ®Google Scholar
• Ekaratanawong, S., et al., 2004. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. Journal of pharmacological sciences, 94 (3), 297–304.
   PubMed Web of Science ®Google Scholar
• Fardel, O., et al., 2015. Nature and uses of fluorescent dyes for drug transporter studies. Expert opinion on drug metabolism & toxicology, 11 (8), 1233–1251.
   PubMed Web of Science ®Google Scholar
• Febvre-James, M., et al., 2018. The JAK1/2 inhibitor ruxolitinib reverses interleukin-6-mediated suppression of drug detoxifying proteins in cultured human hepatocytes. Drug metabolism and disposition, 46 (2), 131–140.
   PubMed Web of Science ®Google Scholar
• Febvre-James, M., Lecureur, V., and Fardel, O., 2020. Potent repression of C-reactive protein (CRP) expression by the JAK1/2 inhibitor ruxolitinib in inflammatory human hepatocytes. Inflammation research, 69 (1), 51–62.
   PubMed Web of Science ®Google Scholar
• Febvre-James, M., et al., 2018. Repression of interferon β-regulated cytokines by the JAK1/2 inhibitor ruxolitinib in inflammatory human macrophages. International immunopharmacology, 54, 354–365.
   PubMed Web of Science ®Google Scholar
• Gay, C., Toulet, D., and Le Corre, P., 2017. Pharmacokinetic drug-drug interactions of tyrosine kinase inhibitors: A focus on cytochrome P450, transporters, and acid suppression therapy: Pharmacokinetic interactions of TKIs. Hematological oncology, 35 (3), 259–280.
   PubMed Web of Science ®Google Scholar
• Gehringer, M., et al., 2014. Novel hinge-binding motifs for Janus kinase 3 inhibitors: a comprehensive structure-activity relationship study on tofacitinib bioisosteres. Chemmedchem, 9 (11), 2516–2527.
   PubMed Web of Science ®Google Scholar
• Gessner, A., König, J., and Fromm, M.F., 2019. Clinical aspects of transporter-mediated drug-drug interactions. Clinical pharmacology and therapeutics, 105 (6), 1386–1394.
   PubMed Web of Science ®Google Scholar
• Harrach, S., et al., 2016. MATE1 regulates cellular uptake and sensitivity to imatinib in CML patients. Blood cancer journal, 6 (9), e470.
   PubMedGoogle Scholar
• Hu, S., et al., 2014. Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations. British journal of cancer, 110 (4), 894–898.
   PubMed Web of Science ®Google Scholar
• Izumi, S., et al., 2013. Substrate-dependent inhibition of organic anion transporting polypeptide 1b1: comparative analysis with prototypical probe substrates estradiol-17β-glucuronide, estrone-3-sulfate, and sulfobromophthalein. Drug metabolism disposition, 41 (10), 1859–1866.
   PubMed Web of Science ®Google Scholar
• Jouan, E., et al., 2014. The mitochondrial fluorescent dye rhodamine 123 is a high-affinity substrate for organic cation transporters (OCTs) 1 and 2. Fundamental & clinical pharmacology, 28 (1), 65–77.
   PubMed Web of Science ®Google Scholar
• Koepsell, H., 2020. Organic cation transporters in health and disease. Pharmacological reviews, 72 (1), 253–319.
   PubMed Web of Science ®Google Scholar
• Kusakizako, T., et al., 2020. Structural biology of the multidrug and toxic compound extrusion superfamily transporters. Biochimica et biophysica Acta (BBA) - biomembranes, 1862 (12), 183154.
   PubMed Web of Science ®Google Scholar
• Le Vée, M., et al., 2019. Neonicotinoid pesticides poorly interact with human drug transporters. Journal of biochemical and molecular toxicology, 33 (10), e22379.
   PubMed Web of Science ®Google Scholar
• Le Vée, M., et al., 2020. Janus kinase-dependent regulation of drug detoxifying protein expression by interleukin-22 in human hepatic cells. International immunopharmacology, 83, 106439.
   PubMed Web of Science ®Google Scholar
• Le Vée, M., et al., 2015., Analysis of sinusoidal drug uptake transporter activities in primary human hepatocytes. In: M. Vinken and V. Rogiers, eds. Protocols in in vitro hepatocyte research. New York, NY: Springer, 287–302.
   Google Scholar
• Malavolta, M., et al., 2020. Exploring the relevance of senotherapeutics for the current SARS-CoV-2 emergency and similar future global health threats. Cells, 9 (4), 909.
   Web of Science ®Google Scholar
• Martínez-Guerrero, L.J., and Wright, S.H., 2013. Substrate-dependent inhibition of human MATE1 by cationic ionic liquids. Journal of pharmacology and experimental therapeutics, 346 (3), 495–503.
   PubMed Web of Science ®Google Scholar
• Morrissey, K.M., et al., 2013. Renal transporters in drug development. Annual review of pharmacology and toxicology, 53 (1), 503–529.
   PubMedGoogle Scholar
• Müller, F., et al., 2013. Role of organic cation transporter OCT2 and multidrug and toxin extrusion proteins MATE1 and MATE2-K for transport and drug interactions of the antiviral lamivudine. Biochemical pharmacology, 86 (6), 808–815.
   PubMed Web of Science ®Google Scholar
• Nies, A.T., et al., 2016. Structure and function of multidrug and toxin extrusion proteins (MATEs) and their relevance to drug therapy and personalized medicine. Archives of toxicology, 90 (7), 1555–1584.
   PubMed Web of Science ®Google Scholar
• Nies, A.T., et al., 2011. Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs). PLoS one, 6 (7), e22163.
   PubMed Web of Science ®Google Scholar
• Nies, A.T., et al., 2009. Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology, 50 (4), 1227–1240.
   PubMed Web of Science ®Google Scholar
• Ogama, Y., et al., 2013. A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. International journal of hematology, 97 (3), 351–359.
   PubMed Web of Science ®Google Scholar
• Pedersen, J.M., et al., 2017. Substrate and method dependent inhibition of three ABC-transporters (MDR1, BCRP, and MRP2). European journal of pharmaceutical sciences, 103, 70–76.
   PubMed Web of Science ®Google Scholar
• Przepiorka, D., et al., 2020. FDA approval summary: ruxolitinib for treatment of steroid‐refractory acute graft‐versus‐host disease. The oncologist, 25 (2), 2019–0627.
   Web of Science ®Google Scholar
• Quintás-Cardama, A., et al., 2011. Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond. Nature reviews drug discovery, 10 (2), 127–140.
   PubMed Web of Science ®Google Scholar
• Roskoski, R., 2016. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacological research, 111, 784–803.
   PubMed Web of Science ®Google Scholar
• Sandoval, P.J., et al., 2018. Assessment of substrate-dependent ligand interactions at the organic cation transporter oct2 using six model substrates. Molecular pharmacology, 94 (3), 1057–1068.
   PubMed Web of Science ®Google Scholar
• Sayyed, K., et al., 2019. Inhibition of organic cation transporter (OCT) activities by carcinogenic heterocyclic aromatic amines. Toxicology in vitro, 54, 10–22.
   PubMed Web of Science ®Google Scholar
• Schmitt, C., et al., 2011. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clinical pharmacology and therapeutics, 89 (5), 735–740.
   PubMed Web of Science ®Google Scholar
• Schwartz, D.M., et al., 2017. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature reviews drug discovery, 16 (12), 843–862.
   PubMed Web of Science ®Google Scholar
• Shi, J., et al., 2015. Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib. Clinical pharmacology and therapeutics, 97 (2), 177–185.
   PubMed Web of Science ®Google Scholar
• Shi, J.G., et al., 2012. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 Phosphate) in healthy volunteers. Journal of clinical pharmacology, 52 (6), 809–818.
   PubMed Web of Science ®Google Scholar
• Shi, J.G., et al., 2011. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. Journal of clinical pharmacology, 51 (12), 1644–1654.
   PubMed Web of Science ®Google Scholar
• Shilling, A.D., et al., 2010. Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. Drug metabolism and disposition, 38 (11), 2023–2031.
   PubMed Web of Science ®Google Scholar
• Sprowl, J.A., et al., 2016. A phosphotyrosine switch regulates organic cation transporters. Nature communications, 7 (1), 10880.
   PubMedGoogle Scholar
• The International Transporter Consortium, 2010. Membrane transporters in drug development. Nature reviews drug discovery, 9 (3), 215–236.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services FDA, 2017. In vitro metabolism- and transporter- mediated drug-drug interaction studies guidance for industry [online]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/vitro-drug-interaction-studies-cytochrome-p450-enzyme-and-transporter-mediated-drug-interactions [Accessed 17 December 2020].
   Google Scholar
• U.S. Department of Health and Human Services FDA, 2020. Guidance for Industry [online]. Available from: https://www.fda.gov/media/134582/download [Accessed 17 December 2020].
   Google Scholar
• Umehara, K., et al., 2019. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug metabolism and personalized therapy, 34 (2).doi:10.1515/dmpt-2018-0042
   PubMedGoogle Scholar
• Vainchenker, W., et al., 2018. JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000research, 7, 82.
   PubMedGoogle Scholar
• Wang, Z.-J., et al., 2008. OCT2 polymorphisms and in-vivo renal functional consequence: studies with metformin and cimetidine. Pharmacogenetics and genomics, 18 (7), 637–645.
   PubMed Web of Science ®Google Scholar
• Zamek-Gliszczynski, M.J., et al., 2018. Transporters in drug development: 2018 ITC recommendations for transporters of emerging clinical importance. Clinical pharmacology and therapeutics, 104 (5), 890–899.
   PubMed Web of Science ®Google Scholar